Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

HIVR4P 2014 was made possible in part by the generous support of the following:

The American people through 1 R13 AI112459-01 from the National Institute of Allergy and Infectious Diseases (NIAID), and from the United States Agency for International Development (USAID). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services or USAID; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

The Government of Canada. The views expressed in conference materials do not necessarily represent the views of the Government of Canada.

The Joint United Nations Programme on HIV/AIDS (UNAIDS). The views expressed in conference materials or publications, by speakers and moderators, or by any conference sponsors do not necessarily reflect the official views or policies of UNAIDS; nor does mention of trade names, commercial practices, or organizations imply endorsement by UNAIDS.

  • Sort by:
  • Browse by:
<< first | < prev page: of 3 records per page: next > | last >>
pages: 1 2 3 sessions: 1 to 25 of 51
Opening Plenary: State of the Art Biomedical Prevention in 2014
Welcome to HIV R4P 2014
Helen Rees
on behalf of 2014 Co-Chairs
Desmond Tutu Award for HIV Prevention and Human Rights
Helen Rees
Keynote Address
Mrs GNM Pandor
MP, Minister of Science and Technology, South Africa
Congratulations to the 2014 Scholars
Jack Whitescarver
NIH Associate Director for AIDS Research and Director, Office of AIDS Research, United States
Prospects for an Antibody-based HIV Vaccine
Lynn Morris
National Institute for Communicable Diseases of the NHLS, Johannesburg, South Africa
Advances in Antiretroviral-Based Prevention Research
Jared Baeten
University of Washington, Seattle, WA, United States
Comprehensive HIV Prevention: Synergy Between Vaccine and Non-Vaccine Modalities
Anthony Fauci
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
from HIV Research for Prevention 2014 on 28 October 2014 08:15-10:30
Oral Abstract Session 01: B Cell Immunogen Design
Structure-based Design of Trimeric V1V2 Antigens
Jason Gorman
NIH/NIAID/VRC, Bethesda, MD, United States
A Native Linked Soluble Trimer of the HIV-1 Spike Displaying Antigenic and Structural Mimetic Properties
Richard Wyatt
IAVI Neutralizing Antibody Center at The Scripps Research Institute, La Jolla, CA, United States
A Recombinant HIV Envelope Trimer Selects for Quaternary Dependent Antibodies Targeting the Trimer Apex
Devin Sok
Scripps Research Institute, La Jolla, CA, United States
An Efficiently Cleaved HIV-1 Subtype C Env that Is Selectively Recognized by Neutralizing Antibodies: A Platform for Immunogen Design
Saikat Boliar
Translational Health Science and Technology Institute, Gurgaon, India
Minimizing Undesirable Epitope Immunodominance on HIV-1 Env Immunogens through Rational Immunogen Modification
Andrew McGuire
Seattle Biomed, Seattle, WA, United States
Uncleaved Soluble gp140 Constructs with Retained Native-like Trimer Conformation and Antigenicity
M. Gordon Joyce
National Institutes of Health, Bethesda, MD, United States
from HIV Research for Prevention 2014 on 28 October 2014 11:00-12:30
Oral Abstract Session 02: Microbicides: Male Partner Engagement and Sexual Behaviors
Engaging Male Partners in Women's Microbicide Use: Evidence from Clinical Trials and Implications for Future Research and Microbicide Introduction
Elizabeth Montgomery
RTI International, San Francisco, CA, United States
Strategies to Improve Male Involvement and Partner Support in the ASPIRE Trial: The Hillbrow Experience
Krishnaveni Reddy
Wits Reproductive Health & HIV Institute, Johannesburg, South Africa
Gel Use Disclosure in an Open-label 1% Tenofovir Gel Trial: Perspectives from Participants, Partners and Community Men in KwaZulu-Natal, South Africa
Kathleen MacQueen
FHI 360, Durham, NC, United States
Exploring Post-coital Intravaginal Cleansing Practices among Women Enrolled in the Microbicides Development Programme MDP 301 Clinical Trial
Mitzy Gafos
MRC Clinical Trials Unit at UCL, London, United Kingdom
Language, Terminology and Understanding of Anal Sex amongst VOICE Participants in Uganda, Zimbabwe and South Africa
Zoe Duby
University of Cape Town, Cape Town, South Africa
Application of a Body Map Tool to Enhance Discussion of Sexual Behaviour in Women: Experiences from MTN 003D
Sarita Naidoo
South African Medical Research Council, Durban, South Africa
from HIV Research for Prevention 2014 on 28 October 2014 11:00-12:30
Oral Abstract Session 03: Animal Model Studies of Microbicides and Injectables
Preclinical Evaluation of TMC-278 LA, a Long-acting Formulation of Rilpivirine, Demonstrates Significant Protection from Vaginal HIV Infection
Olivia Snyder
UNC Chapel Hill, Chapel Hill, NC, United States
HIV PrEP Dose Rationale for Cabotegravir (GSK1265744) Long-acting Injectable Nanosuspension
Bill Spreen
GlaxoSmithKline R&D, Research Triangle Park, NC, United States
Tenofovir Reservoir Intravaginal Rings Provide Superior Pharmacokinetics and Higher Sustained Drug Levels than Tenofovir Matrix Rings
Meredith Clark
CONRAD Eastern Virginia Medical School, Arlington, VA, United States
A Combination Vaginal Ring Releasing Dapivirine and Darunavir
Diarmaid Murphy
Queen's University Belfast, Belfast, United Kingdom
A Novel Intravaginal Ring (IVR) Protects Macaques against SHIV-RT Infection and Reduces HSV-2 Shedding after Repeated SHIV-RT/HSV-2 Co-challenge
Thomas Zydowsky
Population Council, New York, NY, United States
Rectal Specific Gels Containing Maraviroc and/or Tenofovir Protect against Rectal SHIV Transmission in a Macaque Model
Walid Heneine
Centers for Disease Control and Prevention, Atlanta, GA, United States
from HIV Research for Prevention 2014 on 28 October 2014 11:00-12:30
Oral Abstract Session 04: Innate Immunity
SIV- and Vaccine-elicited NK Cell Memory in Rhesus Macaques
R. Keith Reeves
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
Innate Lymphoid Cells are Depleted in HIV Infection
Henrik Kløverpris
KwaZulu-Natal Research Institute for TB&HIV, Durban, South Africa
Impact of Systemic Immune Activation (IA) and Inflammation on the HIV Susceptibility of HIV- individuals with HIV Concordant or Discordant Partners
Shameem Jaumdally
University of Cape Town, Cape Town, South Africa
Do CD16+ NKG2A+ NK Cells Recruited to the Gut Combined with Passively Administered SIV Specific Antibodies Prevent SIV mac251 Acquisition in Macaques?
Namal Liyanage
National Cancer Institute, NIH, Bethesda, MD, United States
Integrated Systems Biology Analysis Reveals Contrasting Role for Innate Immune Response Genes in Conferring Risk of Infection in RV144 Trial
Ali Filali-Mouhim
Vaccine & Gene Therapy Institute of Florida, Port Saint-Lucie, FL, United States
from HIV Research for Prevention 2014 on 28 October 2014 11:00-12:30
Oral Abstract Session 05: Vaccine, Viral Latency and Cure
Durable Suppression of Established Transmitted Founder Replication in Infected BLT Humanized Mice by Vectored ImmunoTherapy
Alejandro Balazs
Harvard University, Cambridge, MA, United States
An HIV DNA Vaccine Delivered by Electroporation and Boosted by rVSV HIV-1 Gag Is Safe and Immunogenic in Healthy HIV-uninfected Adults
Christine Hay
University of Rochester Medical Center, Rochester, NY, United States
Elicitation of Immune Responses by a DNA/MVA Vaccine in ART Treated Patients in a Treatment Interruption Trial
Harriet Robinson
GeoVax, Inc., Smyrna, GA, United States
Early Initiation of ART in Acute HIV Infection (Fiebig I to III) Does Not Preclude the Development of HIV-specific Cellular Immune Responses
Alexandra Schuetz
Armed Forces Research Institute of Medical Sciences - United States Component, Bangkok, Thailand
Engineered Gag-specific T-cell Receptors Redirect Polyclonal CD8+ T-cells to Clear HIV-1-infected CD4+ T-cells from ART-treated Patients
Hongbing Yang
University of Oxford, Oxford, United Kingdom
Structure of HIV-1 gp120 V1V2 in Complex with Human mAb 830A Reveals a 5-Stranded Beta Barrel Conformation and Integrin-binding Site
Ruimin Pan
NYU School of Medicine, New York, NY, United States
from HIV Research for Prevention 2014 on 28 October 2014 11:00-12:30
Oral Abstract Session 06: B Cell Repertoires for Protection
Evolution of Antigen-specific B-cell Receptor Repertoires in Early SIV Infection
Eva Archer
Vaccine Research Center, NIAID, NIH, Bethesda, MD, United States
Role of Intestinal Microbiota in Shaping the B Cell Repertoire in HIV Infection and Env Vaccination
Larry (Huaxin) Liao
Duke University Medical Center, Durham, NC, United States
Plasmablast Phenotype and Mucosal Antibodies to V2 in Vaccine-induced Protection Against SIVmac251
Luca Schifanella
NIH/NCI, Bethesda, MD, United States
Use of Enzyme-digested Virus-like Particles as Probes for Flow Cytometric Sorting of HIV-specific Neutralizing Ab-producing B-cells
Evan Cale
NIAID, National Institutes of Health, Bethesda, MD, United States
Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation
Constantinos Kurt Wibmer
Centre for HIV & STIs, National Institute for Communicable Diseases, NHLS, Johannesburg, South Africa
Maturation Pathway for Antibody 10E8 Deduced Through a Combination of Structure, Next-Generation Sequencing and Bioinformatics
Peter D. Kwong
SBIS, Vaccine Research Center, NIAID/NIH, Bethesda, MD, United States
from HIV Research for Prevention 2014 on 28 October 2014 13:30-15:00
Oral Abstract Session 07: Risk and Prevention for MSM
Characteristics of Young Black Men who Have Sex with Men Enrolled in HPTN 061
Christopher Watson
The George Washington University, Washington, DC, United States
Sexual Behaviour Profile of Gay and Other Men Who Have Sex with Men Enrolled in the PROUD Pre-exposure Prophylaxis Open-label Pilot Study in England
Mitzy Gafos
MRC Clinical Trials Unit at UCL, London, United Kingdom
Structural Stigma Affects Access to Pre- and Post-exposure Prophylaxis and HIV Risk among Men who Have Sex with Men (MSM) in the United States
Catherine Oldenburg
Harvard School of Public Health, Boston, MA, United States
Multiple HIV Counselling Sessions and Safe Sex Practice Helped Bangkok Men who Have Sex with Men Stay HIV-uninfected: Thailand 2006-2014
Wipas Wimonsate
Thailand-MoPH U.S. CDC Collaboration, Nonthaburi, Thailand
Project PrEPARE: High Levels of Medication Adherence with Continued Condomless Sex in U.S. Men who Have Sex with Men in an Oral PrEP Adherence Trial
Kenneth Mayer
Fenway Health, Boston, MA, United States
from HIV Research for Prevention 2014 on 28 October 2014 13:30-15:00
Oral Abstract Session 08: Correlates of Protection and Exposure
Evaluation of Mucosal Tissue Explants as ex vivo Surrogates of in vivo Vaccination of Non-human Primates (NHPs) and Humans
Carolina Herrera
Imperial College, London, United Kingdom
Evolutionary Analysis Identifies an MX2 Haplotype Associated with Natural Resistance to HIV-1 Infection
Irma Saulle
University of Milan, Milan, Italy
Systematic Analysis of HIV-1 Env Epitopes of Two HLA Class I Alleles Associate with Different Rates of HIV Infection in the Pumwani Sex Worker Cohort
Meika Richmond
Public Health Agency of Canada, Winnipeg, Canada
Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
Paul Edlefsen
Fred Hutchinson Cancer Research Center, Seattle, WA, United States
SIVsmE660 Envelope Variants from Breakthrough Infections Following DNA/MVA Vaccination of Rhesus Macaques are Susceptible to Neutralization
Stacey Smith
Emory University, Atlanta, GA, United States
Microbicide-vaccine Combination Provides Significant Protection against Vaginal SHIV-162P3 Challenge in Cynomolgous Monkeys
Robin Shattock
Imperial College, London, United Kingdom
from HIV Research for Prevention 2014 on 28 October 2014 13:30-15:00
Oral Abstract Session 09: Engaging, Recruiting and Retaining Trial Participants
Why Women at High Risk for HIV-1 Infection Did Not Join the VOICE Study in Uganda: A Qualitative Community Study
Teopista Nakyanzi
Makerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda
Community Engagement in a Volatile Community Post-marikana for a Phase III Microbicide Ring Trial
Cheryl Louw
Madibeng Centre for Research, Brits, South Africa
Employing a Youth-centered Approach to Investigate HIV Risk among Adolescents and Young Adults in an HIV Hyper-endemic Setting
Janan Dietrich
Perinatal HIV Research Unit, Soweto, South Africa
WhatsApp!: Use of Mobile Technology in Optimizing ASPIRE Study Retention and Adherence at the Wits Reproductive Health and HIV Institute, Johannesburg
Krishnaveni Reddy
Wits Reproductive Health & HIV Institute, Johannesburg, South Africa
Turning around Poor Retention: A Cape Town Experience
Karen Dominguez
Desmond Tutu HIV Foundation, Cape Town, South Africa
Reasons Boston MSM Enrolled in Placebo Controlled PrEP Trials Did Not Continue Using PrEP when it Was Available in an Open Label Study
Christopher Chianese
Fenway Health, Boston, MA, United States
from HIV Research for Prevention 2014 on 28 October 2014 13:30-15:00
Oral Abstract Session 10: Bacterial Vaginosis and HSV-2: Impact on Genital Immunity
The Effects of Hormones and Vaginal Microflora on the Content of MUC1, MUC4, MUC5AC and MUC7 in the Cervicovaginal Fluid (CVF)
Bernard Moncla
University of Pittsburgh, Pittsburgh, PA, United States
HSV-2-driven Changes in α4β7 Expression Correlate with Increased Susceptibility to SHIV ex vivo and in vivo
Elena Martinelli
Population Council, New York, NY, United States
Incident Herpes Simplex Virus Type 2 Associated with HIV Infection in Phambili
James Kublin
HIV Vaccine Trials Network, Seattle, WA, United States
Mucosal Integrity Factors Are Perturbed during Bacterial Vaginosis: A Proteomic Analysis
Adam Burgener
Public Health Agency of Canada, Winnipeg, Canada
Effect of Bacterial Vaginosis on Markers of Genital Tract Inflammation and Mucosal Immunity: Mechanisms for Susceptibility to HIV Infection
Andrea Thurman
CONRAD, Norfolk, VA, United States
Association of Tenofovir (TFV) Detection with Reduced Risk of Herpes Simplex virus Type-2 (HSV-2) Acquisition in the VOICE (MTN 003) Study
Jeanne Marrazzo
University of Washington, Seattle, WA, United States
from HIV Research for Prevention 2014 on 28 October 2014 13:30-15:00
Symposium 01: Overcoming Barriers to Broadly Neutralizing Antibody Induction
Prevention Strategies Based on HIV-1 Neutralizing Antibodies
John Mascola
National Institutes of Health, Bethesda, MD, United States
Broadly Neutralizing Antibody Responses in HIV-1 Infection: Insights from a Large Cohort and from Individuals
Elise Landais
IAVI Neutralizing Antibody Center at The Scripps Research Institute, La Jolla, CA, United States
HIV Envelope Interactions with the Progenitor BCRs of Narrow and Broadly Neutralizing Antibodies
Leonidas Stamatatos
Seattle Biomedical Research Institute, Seattle, WA, United States
HIV-1 Mimicry of Host Antigens: Hiding in Plain Sight to Evade Immunity
Garnett Kelsoe
Duke University, Durham, NC, United States
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Symposium 02: Advances in Animal Models
Non-Human Primate Models for New Prevention Strategies of HIV Transmission
Roger Le Grand
CEA, Fontenay-aux-Roses, France
How Mice to Monkeys Inform Human B Cell Repertoire Responses
Gunilla Karlsson Hedestam
Karolinska Institutet, Stockholm, Sweden
Prevention Studies in Nonhuman Primate Models
Jeffrey Lifson
National Institutes of Health, Bethesda, MD, United States
The Role of Humanized Mice in Advancing HIV Vaccine and Eradication Studies
Todd Allen
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Symposium 03: Treatment as Prevention: The Promise and the Perils
No Time to Lose - The Importance of Early HIV Infection
Kimberly Powers
The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
A Tale of Four Treatment-as-Prevention Trials in Africa
Frank Tanser
University of KwaZulu-Natal, Mtubatuba, South Africa
Treatment as Prevention - How Can We Predict Success?
Deenan Pillay
Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa
TasP Promises...But What Is The Reality?
Valerie Delpech
Public Health England, London, United Kingdom
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Symposium 04: Building Combination Prevention Trials
Building Combination Prevention: Trial Designs
Helen Weiss
London School of Hygiene & Tropical Medicine, London, United Kingdom
Combination Prevention: From Trials to Implementation
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
The Role of Mathematical Modeling to Design, Conduct, Interpret and Replicate HIV Prevention Trials
Marie-Claude Boily
Imperial College London, London, United Kingdom
Scalable Adherence Interventions
Terrence Blaschke
Bill and Melinda Gates Foundation, Seattle, WA, United States
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Plenary 02: Targeting Biomedical Preventions to Different At-Risk Populations
Tailoring Biomedical Preventive Interventions for Key Populations: Towards Safety, Efficacy, Effectiveness
Chris Beyrer
Johns Hopkins Bloomberb School of Public Health, Baltimore, MD, United States
Working with Special Populations within HIV Prevention Intervention Programs and Trials
Bridget Haire
University of New South Wales, Sydney, Australia
Tailoring Interventions to Different Populations
Pontiano Kaleebu
MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
from HIV Research for Prevention 2014 on 29 October 2014 08:30-10:00
Oral Abstract Session 11: Vaccine Development: Emerging Insights
African Early Infection Cohort as a Platform for Vaccine Discovery: The IAVI Protocol C Experience
Jill Gilmour
IAVI Human Immunology Lab, London, United Kingdom
Intradermal HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees
Charlotta Nilsson
The Public Health Agency of Sweden, Solna, Sweden
VLP-expressing DNA/MVA Vaccines: The Effect of Schedule and Regimen on Antibody Magnitude and Avidity
Susan Buchbinder
San Francisco Department of Public Health, San Francisco, CA, United States
Vaccine Enhancement Confirmed among Men in HVTN 503-S, Final Results from a Recall Study of Phambili Participants
Zoe Moodie
Fred Hutchinson Cancer Research Center, Seattle, WA, United States
HIV-specific Antibody in Rectal Secretions Following Late Boosts in RV144 Participants (RV305)
Siriwat Akapirat
Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
HVTN 097: Evaluation of the RV144 Vaccine Regimen in HIV Uninfected South African Adults
Glenda Gray
South African Medical Research Council, Cape Town, South Africa
from HIV Research for Prevention 2014 on 29 October 2014 11:00-12:30
Oral Abstract Session 12: Towards Broadly Neutralizing Antibody Induction
Maturation of Broadly Neutralizing V1V2-directed Antibodies in the Context of Autologous Viral Escape
Jinal Bhiman
Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa
Development of a V1/V2-targeting Quaternary-specific Broadly Neutralizing Lineage
Elise Landais
The International AIDS Vaccine Initiative, La Jolla, CA, United States
Development of Broadly Neutralizing Anti-HIV-1 Antibodies during Natural Infection through Early Epitope Acquisition and Subsequent Maturation
D Noah Sather
Seattle Biomedical Research Institute, Seattle, WA, United States
Investigating Epitope Exposure on Native Trimers
Sergey Menis
The Scripps Research Institute, La Jolla, CA, United States
An Inflammatory Profile that Predicts the Development of Neutralizing Antibody Breadth
Anne Sophie Dugast
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 Vaccinees
Michael Moody
Duke University Medical Center, Durham, NC, United States
from HIV Research for Prevention 2014 on 29 October 2014 11:00-12:30
Oral Abstract Session 13: ARV Exposure & Efficacy in the Genital Tract
Defining Pharmacokinetic and Pharmacodynamic linkages between Genital Tissue and Lumen Compartments
Charlene Dezzutti
University of Pittsburgh, Pittsburgh, PA, United States
Phase 1 Safety & Pharmacokinetic Trial of a Polyurethane Tenofovir Disoproxil Fumarate Intravaginal Ring in Healthy, Low-risk U.S. Women
Marla Keller
Albert Einstein College of Medicine, Bronx, NY, United States
Multicompartmental Pharmacokinetics of Tenofovir 1% Gel Using the BAT 24 Regimen Versus Daily and Single Pericoital Dosing
Jill Schwartz
CONRAD Eastern Virginia Medical School, Arlington, VA, United States
Population Pharmacokinetic Model of Vaginal Tenofovir 1% Gel in the Cervicovaginal Fluid
Kuo-Hsiung Yang
UNC Eshelman School of Pharmacy, Chapel Hill, NC, United States
Sex Matters: MTN-011 Phase 1 Study on the Impact of Sex on Tenofovir Gel Pharmacokinetics (PK) and Pharmacodynamics (PD)
Betsy Herold
Albert Einstein College of Medicine, Bronx, NY, United States
Population Pharmacokinetic Modelling of Dapivirine
Annalene Nel
International Partnership for Microbicides, Paarl, South Africa
from HIV Research for Prevention 2014 on 29 October 2014 11:00-12:30
Oral Abstract Session 14: Host Factors: Injury, Acquisition and Infection
Protective HLA Alleles Reduce Markers of Gut Damage and Microbial Translocation and Preserve the Cellular Immune Response during Acute HIV-1 Infection
Daniel Claiborne
Emory University, Atlanta, GA, United States
Combined Effect of HLA-C*04:01 and KIR2DS4 on Increased HIV Viral Loads
Alex Olvera
IrsiCaixa AIDS Research Institute - HIVACAT, Badalona, Spain
Immune Correlates Identified in the RV144 Vaccine Efficacy Trial Impact HIV-1 Acquisition Only in the Presence of Certain HLA Class II Genes
Rasmi Thomas
U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, Silver Spring, MD, United States
Transmitted Escape Mutations Lead to Accelerated HIV-1 Disease Progression and Largely Define the Relative Contribution of HLA Alleles to Control
Jonathan Carlson
Microsoft Research, Redmond, WA, United States
Inhibiting the Host Exonuclease TREX1 Induces a Localized and Protective Host Interferon Response against Acute HIV Infection in vivo
Lee Adam Wheeler
Harvard Medical School, Boston, MA, United States
Candidate Loci Associated with AIDS Virus Replication Identified by Whole Genome Sequencing of SIV-Infected Macaques
David O'Connor
University of Wisconsin - Madison, Madison, WI, United States
from HIV Research for Prevention 2014 on 29 October 2014 11:00-12:30
Oral Abstract Session 15: PrEP and Microbicide Adherence in Women
Hidden Heterogeneity: Uncovering Patterns of Adherence in Microbicide Trials
Lori Miller
London School of Hygiene & Tropical Medicine, London, United Kingdom
To Give or Not to Give PK Results: An Ethical Dilemma for Researchers & Regulators in Uganda
Juliane Etima
Makerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda
The Effect of Presentation of Pharmacokinetic (PK) Drug Results on Self-reported Study Product Adherence among VOICE Participants in Zimbabwe
Petina Musara
University of Zimbabwe-University of California San Francisco Collaborative Research Programme, Harare, Zimbabwe
Disclosure of Pharmacokinetic (PK) Drug Results Promotes Open Discourse on Non- adherence among Women in VOICE
Ariane van der Straten
Women's Global Health Imperative; RTI International, San Francisco, CA, United States
Bounding the Seasons of Pre-exposure Prophylaxis: When and why Women at Higher Risk of HIV Might Suspend Use
Kawango Agot
Impact Research and Development Organization, Kisumu, Kenya
Proportion Days Covered as a Measure of Adherence in US PrEP Subjects
Keith Rawlings
Gilead Sciences, Foster City, CA, United States
from HIV Research for Prevention 2014 on 29 October 2014 11:00-12:30
Oral Abstract Session 16: Novel Vaccine Concepts
Live Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans
Mark Connors
NIAID/LIR, Bethesda, MD, United States
Non-HIV-derived (Poly)peptides as Primary Immunogens Followed by Envelope Boost Elicit Cross-clade Neutralizing HIV-1 Antibodies
Mei-Yun Zhang
University of Hong Kong, Hong Kong, China
Mechanisms of Protection Observed with Varicella Zoster Virus as a Vaccine Vector in the SIV Macaque Model
Catia Perciani
University of Toronto, Toronto, Canada
Genetic Assessment of B-cell Responses Following Immunization with HIV Env Protein and Adjuvants or SHIV (AD8) Infection in Nonhuman Primates
Joseph Francica
NIH, Bethesda, MD, United States
Expanded Epitope Recognition by Vaccination with DNA Encoding Novel Immunogens Comprising HIV Conserved Elements
Barbara Felber
National Cancer Institute at Frederick, Frederick, MD, United States
Vaccine Induced Distinct Circulating Memory CD4+ T-cells with T-follicular Helper Cell Commitment in Humans
Antje Heit
Fred Hutchinson Cancer Research Center, Seattle, WA, United States
from HIV Research for Prevention 2014 on 29 October 2014 13:30-15:00
Oral Abstract Session 17: Mucosal Target and Effector Cells
Immune Activation and HIV Target Cells in the Adolescent Female Genital Tract
Smritee Dabee
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
Functional Dynamics of the Interaction between HIV gp120 and α4β7
James Arthos
NIAID, National Institutes of Health, Bethesda, MD, United States
Preferential HIV Susceptibility of Specific CD4+ T Cell Subsets in the Cervix
Vineet Joag
University of Toronto, Toronto, Canada
Expression of MAIT Cells in Blood and Genital Mucosa of HIV Infected and Uninfected Women
Anna Gibbs
Karolinska Institutet, Stockholm, Sweden
Rapid Loss of Th17 Cells after acute SIV Infection May Underlie Mucosal Dysfunction
Nichole Klatt
University of Washington, Seattle, WA, United States
No Increase in Activated T Cells and Limited Increase in Adenovirus-specific T Cells in Colon and Rectal Mucosa Following HIV-1 DNA/rAd5 Immunization
Stephen De Rosa
Fred Hutchinson Cancer Research Center, Seattle, WA, United States
from HIV Research for Prevention 2014 on 29 October 2014 13:30-15:00
Oral Abstract Session 18: Evaluation of Novel Interventions
HbAHP-25 Inhibits HIV-1 Entry into Cells and Neutralizes gp120 Induced Inflammation
Tahir Bashir
National Institute for Research in Reproductive Health [NIRRH], Mumbai, India
Bypass of Quality Control in Protein Folding Pathways Induces Specific Misfolding of HIV Envelope V2 Loop: Implications for Iminosugars as Antivirals
Simon Spiro
University of Oxford, Oxford, United Kingdom
A Role for Scavenger-like Lymphocyte Receptor CD6 in HIV-1 Viral Infection
Núria Climent
CELLEX-IDIBAPS-HIVACAT, Barcelona, Spain
Testing a Fast-dissolving Tablet Containing a Recombinant Live Biotherapeutic Product, MucoCept-CVN, in the Non-human Primate Model for Colonization
Laurel Lagenaur
NCI, Bethesda, MD, United States
The role of Semen on Vaginal HIV-1 Transmission and on the Efficacy of Maraviroc as a Topically Applied Microbicide
Olivia Snyder
UNC Chapel Hill, Chapel Hill, NC, United States
Post Coital Assessment of Topical Microbicide Formulations in the Macaque Model
Dorothy Patton
University of Washington, Seattle, WA, United States
from HIV Research for Prevention 2014 on 29 October 2014 13:30-15:00
Oral Abstract Session 19: Good Participatory Practices in HIV Prevention
Inclusion of Transgender and Gender Non-conforming Communities in Preventive HIV Vaccine Research at the HIV Vaccine Trials Network (HVTN)
Gail Broder
Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Breaking Barriers: Does Research Interests Match those of Lesbian, Gay, Bisexual and Transgender (LGBT) Community Needs in Kenya?
Jonah Chinga
Minority Persons Empowerment Group (MPEG), Thika, Kenya
Words & Images Have Consequences: Gay Men, Prevention Research and the Double-edged Sword of the Media
Cindra Feuer
AVAC, New York, NY, United States
The Utilization of Good Participatory Practice (GPP) during the Planning and Implementation of a PrEP Study among Black MSM
Jonathan Lucas
FHI 360, Durham, NC, United States
Assessing GPP in Action: How FACTS 001 Formalised the Implementation of Stakeholder Engagement in a Large-scale Prevention Trial
Sinazo Pato
Wits Reproductive Health & HIV Institute, Johannesburg, South Africa
Challenges with Participant Reimbursement: Experiences from CAPRISA 008 - A Post-trial Access Study
Kathryn Mngadi
Centre for the Programme of AIDS Research in South Africa, Durban, South Africa
from HIV Research for Prevention 2014 on 29 October 2014 13:30-15:00
<< first | < prev page: of 3 records per page: next > | last >>
pages: 1 2 3 sessions: 1 to 25 of 51